Christopher Glisson, DO
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,005 of the $124,923 with a category attached, or 74.4%. AstraZeneca accounts for 73.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $47,362 and has fallen 98.1% since, to $910 in 2025. Among neurology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $827.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$92K
- Amgen$20K
- Argenx US, Inc.$8K
- Catalyst Pharmaceuticals, Inc.$4K
- Genentech USA, Inc.$269
- Eisai Inc.$224
- plus $1K from 10 others
What the payments were for
- Consulting fees$16,08513%
- Speaking & faculty fees$93,00574%
- Travel & lodging$11,7959%
- Food & beverage$3,8263%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $92,196 |
| Amgen | 21 | $19,681 |
| Argenx US, Inc. | 10 | $7,852 |
| Catalyst Pharmaceuticals, Inc. | 8 | $3,700 |
| Genentech USA, Inc. | 2 | $269 |
| Eisai Inc. | 2 | $224 |
| UCB, Inc. | 6 | $160 |
| Novartis | 2 | $152 |
| Eyepoint US, Inc. | 1 | $125 |
| Lundbeck LLC | 1 | $125 |
| TG Therapeutics, Inc. | 1 | $112 |
| Johnson & Johnson | 1 | $100 |
| Teva Pharmaceuticals USA, Inc. | 1 | $91 |
| E.r. Squibb & Sons, L.L.C. | 2 | $72 |
| AbbVie | 3 | $44 |
| Shire North American Group Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,923 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 33 | $1,894 |
| Ropinirole Hcl | 11 | $942 |
| Memantine Hcl | 26 | $833 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 44 | $811 |
| Primidone | 38 | $599 |
| Gabapentin | 22 | $413 |
| Donepezil Hcl | 12 | $269 |
| Prednisone | 15 | $150 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tulsa
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Tania ReynaTulsa$353K
- Alok PasrichaTulsa$81K
- Aimee BorazanciTulsa$75K
- Randall WebbTulsa$31K
- Todd DunawayTulsa$26K
- Jeremy SalasTulsa$20K
- Jorge GonzalezTulsa$19K
- Kenny SusantoTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.